# FDA calendar: upcoming PDUFA dates, advisory committees and readouts

Canonical: https://sec-api.dev/fda-calendar

> 224 FDA catalysts fall between November 16, 2026 and December 16, 2026: 9 PDUFA dates and 0 advisory committee meetings. Next: Savara Inc (SVRA) on November 22, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA PDUFA dates?

224 FDA catalysts fall between November 16, 2026 and December 16, 2026: 9 PDUFA dates and 0 advisory committee meetings. Next: Savara Inc (SVRA) on November 22, 2026. PDUFA dates: Savara Inc (SVRA) on November 22, 2026; deramiocel (CAPR) on November 22, 2026; venglustat (SNY) on November 25, 2026; ribitol (BBIO) on November 27, 2026; bezuclastinib (COGT) on November 30, 2026; and 4 more. [Calendar and source filings](https://sec-api.dev/fda-calendar)

Source: SEC Form 10-Q, accession 0001193125-26-453535, https://www.sec.gov/Archives/edgar/data/1160308/000119312526453535/svra-20260930.htm (retrieved 2026-11-12). Last confirmed 2026-11-09. Cite: https://sec-api.dev/fda-calendar#answer

## Next 30 days

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| November 2026 | [AZD0901 primary completion](https://sec-api.dev/pdufa/azd0901) | AZN | Gastric Cancer; Gastroesophageal Junction Cancer; Biliary Tract Cancer | scheduled | "NCT06219941 (AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-11-17 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06219941)) |
| November 2026 | [AAA617 primary completion](https://sec-api.dev/pdufa/aaa617) | NVS | Metastatic Castration Resistant Prostate Cancer (mCRPC) | scheduled | "NCT06894511 (An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-17 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06894511)) |
| November 2026 | [Sotyktu (deucravacitinib) primary completion](https://sec-api.dev/pdufa/deucravacitinib) | BMY | Sjögren's Syndrome | scheduled | "NCT05946941 (A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11-18 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05946941)) |
| November 2026 | [JNJ-95597528 primary completion](https://sec-api.dev/pdufa/jnj-95597528) | JNJ | Dermatitis, Atopic | scheduled | "NCT07230860 (A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-19 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07230860)) |
| November 2026 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Endometrial Neoplasms | scheduled | "NCT04634877 (Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11-20 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04634877)) |
| November 2026 | [Povofortay (povorcitinib) primary completion](https://sec-api.dev/pdufa/povorcitinib) | INCY | Moderate to Severe Asthma | scheduled | "NCT05851443 (A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-20 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05851443)) |
| November 2026 | [Nimacimab primary completion](https://sec-api.dev/pdufa/nimacimab) | SKYE | Obesity | scheduled | "NCT06577090 (Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-20 (ESTIMATED); Lead Sponsor Skye Bioscience, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06577090)) |
| November 22, 2026 | [Savara Inc PDUFA date](https://sec-api.dev/companies/svra/catalysts) | SVRA |  | scheduled | "The FDA determined that the Company's responses to recent information requests by the Agency during its review constituted a major amendment to the BLA, resulting in a three-month extension of the Prescription Drug User Fee Act ("PDUFA") target action date to November 22, 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1160308/000119312526453535/svra-20260930.htm)) |
| November 22, 2026 | [Deramiocel PDUFA date](https://sec-api.dev/pdufa/deramiocel) | CAPR | rare diseases, today | scheduled | "Deramiocel Biologics License Application (BLA) for Duchenne muscular dystrophy (DMD) under FDA review; PDUFA target action date of November 22, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1133869/000110465926125150/capr-ex99d1.htm)) |
| November 2026 | [Jemperli (dostarlimab) primary completion](https://sec-api.dev/pdufa/dostarlimab) | GSK | Neoplasms, Colon | scheduled | "NCT06567782 (A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-11-23 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06567782)) |
| November 2026 | [PCV-20 primary completion](https://sec-api.dev/pdufa/pcv-20) | GSK | Chickenpox | scheduled | "NCT06693895 (A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-11-23 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06693895)) |
| November 2026 | [Dtpa primary completion](https://sec-api.dev/pdufa/dtpa) | GSK | Diphtheria-Tetanus-acellular Pertussis Vaccines | scheduled | "NCT07596199 (A Study on the Immune Response and Safety of a Combined Vaccine Against Diphtheria, Tetanus and Acellular Pertussis (dTpa) in Japanese Healthy Pregnant Women): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11-23 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07596199)) |
| November 2026 | [Karxt primary completion](https://sec-api.dev/pdufa/karxt) | BMY | Alzheimer Disease | scheduled | "NCT06585787 (A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-11-24 (ESTIMATED); Lead Sponsor Karuna Therapeutics, Inc., a Bristol Myers Squibb company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06585787)) |
| November 2026 | [Tx000045- dose a primary completion](https://sec-api.dev/pdufa/tx000045) | TECX | Pulmonary Hypertension; Heart Failure With Preserved Ejection Fraction | scheduled | "NCT06616974 (A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-24 (ESTIMATED); Lead Sponsor Tectonic Therapeutic." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06616974)) |
| November 25, 2026 | [Venglustat PDUFA date](https://sec-api.dev/pdufa/venglustat) | SNY |  | scheduled | "The target action date for the FDA decision is November 25, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1121404/000112140426000008/pressreleaseq22026english.htm)) |
| November 2026 | [Wayrilz (rilzabrutinib) primary completion](https://sec-api.dev/pdufa/rilzabrutinib) | SNY | Immune Thrombocytopenia | scheduled | "NCT07216079 (Rilzabrutinib for the Adult Participants With Chronic ITP Who Have Completed Phase 3 Study in Japan): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11-25 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07216079)) |
| November 2026 | [ZEJULA (niraparib) primary completion](https://sec-api.dev/pdufa/niraparib) | GSK | Neoplasms | scheduled | "NCT03981796 (A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11-26 (ESTIMATED); Lead Sponsor Tesaro, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03981796)) |
| November 27, 2026 | [Ribitol PDUFA date](https://sec-api.dev/pdufa/ribitol) | BBIO |  | scheduled | "- BBP-418 for LGMD2I/R9 has a November 27, 2026 PDUFA date, with Priority Review." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1743881/000174388126000033/bbio-20260930xex991.htm)) |
| November 2026 | [Yellow fever vaccine (live) primary completion](https://sec-api.dev/pdufa/yellow-fever-vaccine-live) | SNY | Yellow Fever Immunization | scheduled | "NCT07103148 (A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric Population): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11-28 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07103148)) |
| November 2026 | [Nurtec Odt (rimegepant sulfate) primary completion](https://sec-api.dev/pdufa/rimegepant) | PFE | Menstrual Migraine | scheduled | "NCT06641466 (A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-11-29 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06641466)) |
| November 30, 2026 | [Bezuclastinib PDUFA date](https://sec-api.dev/pdufa/bezuclastinib) | COGT |  | scheduled | "Preparing for anticipated bezuclastinib launch in GIST; PDUFA action date November 30, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1622229/000119312526449926/cogt-ex99_1.htm)) |
| November 30, 2026 | [Povetacicept PDUFA date](https://sec-api.dev/pdufa/povetacicept) | VRTX | immunoglobulin A nephropathy | scheduled | "•The BLA submission for accelerated approval of povetacicept in IgAN is under priority review by the U.S. FDA, with an assigned PDUFA target action date of November 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000287/ex-991_q32026.htm)) |
| November 2026 | [NeuroPace Inc primary completion](https://sec-api.dev/companies/npce/catalysts) | NPCE | Epilepsy; Lennox Gastaut Syndrome; Lennox-Gastaut Syndrome, Intractable | scheduled | "NCT05339126 (RNS System LGS Feasibility Study): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-30 (ESTIMATED); Lead Sponsor NeuroPace." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05339126)) |
| November 2026 | [Joenja® (leniolisib) primary completion](https://sec-api.dev/pdufa/leniolisib) | PHAR | APDS | scheduled | "NCT05438407 (Pediatric Patients Aged 4 to 11 Years With APDS): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11-30 (ESTIMATED); Lead Sponsor Pharming Technologies B.V.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05438407)) |
| November 2026 | [AU-011 primary completion](https://sec-api.dev/pdufa/au-011) | AURA | Eye Cancer; Primary Cancer | scheduled | "NCT06643884 (Suprachoroidal Administration in Subjects With Metastases to the Choroid): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-11-30 (ESTIMATED); Lead Sponsor Aura Biosciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06643884)) |
| November 2026 | [TAK-360 primary completion](https://sec-api.dev/pdufa/tak-360) | TAK | Idiopathic Hypersomnia | scheduled | "NCT06812078 (A Study of TAK-360 in Adults With Idiopathic Hypersomnia): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-11-30 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06812078)) |
| November 2026 | [TAK-360 primary completion](https://sec-api.dev/pdufa/tak-360) | TAK | Narcolepsy Type 2 | scheduled | "NCT06952699 (A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-11-30 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06952699)) |
| November 2026 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Hepatocellular Carcinoma | scheduled | "NCT07081633 (Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-30 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07081633)) |
| November 2026 | [Mr-130a-01 contraceptive transdermal patch, containing norelgestromin (ngmn) primary completion](https://sec-api.dev/pdufa/mr-130a-01-contraceptive-transdermal-patch-containing-norelgestromin-ngmn) | VTRS | Contraception | scheduled | "NCT07365904 (Investigating Ovulation Inhibition for Use as a Contraceptive): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-11-30 (ESTIMATED); Lead Sponsor Mylan Pharmaceuticals Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07365904)) |
| November 2026 | [Oral bge-102 primary completion](https://sec-api.dev/pdufa/oral-bge-102) | BIOA | Obesity and Cardiovascular Risk | scheduled | "NCT07656727 (A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-30 (ESTIMATED); Lead Sponsor BioAge Labs, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07656727)) |
| Dec 2026 | [Orencia (abatacept) PDUFA date](https://sec-api.dev/pdufa/abatacept) | RDY |  | scheduled | "As we speak today, the goal date for abatacept is in mid-December 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1135951/000157587226000536/rdy0931_ex99-1.htm)) |
| Dec 2026 | [Rezpegaldesleukin trial start](https://sec-api.dev/pdufa/rezpegaldesleukin) | NKTR |  | scheduled | "We intend to initiate a global registrational trial (ZENITH AA-1) in December 2026 to evaluate rezpegaldesleukin in patients who are 12 years of age or older with severe-to-very-severe alopecia areata." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/906709/000119312526458868/nktr-20260930.htm)) |
| Dec 2026 | [IGC Pharma, Inc. topline data readout](https://sec-api.dev/companies/igc/catalysts) | IGC |  | scheduled | "Company anticipates reporting topline results during the December 2026/January 2027 timeframe, subject to clinical trial and data management uncertainties." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1326205/000118518526005237/igc10q093026.htm)) |
| Dec 2026 | [Annamycin topline data readout](https://sec-api.dev/pdufa/annamycin) | MBRX |  | scheduled | "- MIRACLE trial advancing toward planned 90-patient enrollment milestone in September 2026 with the unblinded efficacy readout in December 2026 to February 2027 timeframe" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1659617/000143774926027835/ex_1004839.htm)) |
| Dec 2026 | [Ersodetug topline data readout](https://sec-api.dev/pdufa/ersodetug) | RZLT | hypoglycemia caused | scheduled | "Topline results expected mid - December 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm)) |
| Dec 2026 | [Azetukalner topline data readout](https://sec-api.dev/pdufa/azetukalner) | XENE | Major Depressive Disorder | scheduled | "Enrollment in Phase 3 X-NOVA2 study of azetukalner in MDD completed with topline data readout now expected in December 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1582313/000119312526453521/xene-ex99_1.htm)) |
| Dec 2026 | [BRUKINSA® (zanubrutinib) interim data readout](https://sec-api.dev/pdufa/zanubrutinib) | CRIS |  | scheduled | "To date, 12 patients have been enrolled in the study with initial data expected in December 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1108205/000110465926127041/tm2629651d1_ex99-1.htm)) |
| Dec 2026 | [Tabirafusp topline data readout](https://sec-api.dev/pdufa/tabirafusp) | KOD | macular edema secondary to inflammation | scheduled | "These forward-looking statements are not based on historical fact and include statements regarding: the planned multi-indication BLA submission for Zenkuda in the fourth quarter of 2026; the planned BLA submission for KS-101 in the second quarter of 2027; acceleration of the tabirafusp development program and the status of enrollment in, and expectations regarding the ALTO study; planned post-hoc analyses to identify patients that can benefit from IL-6 inhibition; and expectations regarding the announcement of topline data December 2026 for KSI-101 in the Phase 3 PEAK study in patients with macular edema secondary to inflammation (MESI)." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1468748/000119312526403481/d185059dex991.htm)) |
| Dec 2026 | [KSI-101 topline data readout](https://sec-api.dev/pdufa/ksi-101) | KOD |  | scheduled | "Phase 3 PEAK Study (KSI-101) - Pivotal Analysis 1 Topline Data Expected December 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1468748/000119312526458248/kod-ex99_1.htm)) |
| Dec 2026 | [Indegene NDA/BLA submission](https://sec-api.dev/pdufa/indegene) | CING |  | scheduled | "Company expects to resubmit the new drug application (NDA) for CTx-1301 between December 2026 and January 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1862150/000149315226051841/ex99-1.htm)) |
| Dec 2026 | [EP-104 interim data readout](https://sec-api.dev/pdufa/ep-104) | EPRX |  | scheduled | "In December 2026, the Company expects to release interim data from the Phase 2b portion of the RESOLVE study." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1581178/000119312526455405/d98561dex992.htm)) |
| Dec 2026 | [Claseprubart topline data readout](https://sec-api.dev/pdufa/claseprubart) | DNTH | Multifocal Motor Neuropathy | scheduled | "2 MoMeNtum Top-line Data Anticipated Q4'26 Q4'26" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000029/dnth-ex99_1.htm)) |
| Dec 2026 | [Empasiprubart topline data readout](https://sec-api.dev/pdufa/empasiprubart) | ARGX | Multifocal Motor Neuropathy (MMN); MMN | scheduled | "•Topline results from the Phase 3 EMPASSION study (MMN) expected in December 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1697862/000169786226000034/a02earningspressreleaseq3.htm)) |
| Dec 2026 | [Palazestrant interim data readout](https://sec-api.dev/pdufa/palazestrant) | OLMA |  | scheduled | "The Phase 1b/2 study investigating palazestrant in combination with atirmociclib has completed enrollment and we expect to present initial data at the San Antonio Breast Cancer Symposium (SABCS) in December 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1750284/000119312526454421/olma-20260930.htm)) |
| Dec 2026 | [Imu-838 tablets topline data readout](https://sec-api.dev/pdufa/imu-838) | IMUX | relapsing multiple sclerosis | scheduled | "The company's lead investigational asset, vidofludimus calcium (IMU-838), is currently being evaluated in Phase 3 clinical trials in relapsing multiple sclerosis, with top-line data expected to be available in December 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1280776/000149315226051543/ex99-1.htm)) |
| Dec 2026 | [Tedromer topline data readout](https://sec-api.dev/pdufa/tedromer) | KOD |  | scheduled | "Phase 3 PEAK Study - Pivotal Analysis 1 Topline Data Expected December 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1468748/000119312526349107/kod-ex99_1.htm)) |
| Dec 2026 | [Autolus Therapeutics plc interim data readout](https://sec-api.dev/companies/autl/catalysts) | AUTL |  | scheduled | "AUTO8 in Light-Chain Amyloidosis The Phase 1 ALARIC trial evaluating AUTO8 in light-chain amyloidosis is ongoing and initial data are expected to be reported at ASH in December 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1730463/000173046326000141/autlex-991pr111026.htm)) |
| Dec 2026 | [Kodiak Sciences Inc. topline data readout](https://sec-api.dev/companies/kod/catalysts) | KOD |  | scheduled | "We have completed enrollment of the first 300-patient pivotal cohort in the PEAK trial, supporting Pivotal Analysis 1, with topline clinical data from the 24-week primary endpoint on track for a December 2026 release." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1468748/000119312526458248/kod-ex99_1.htm)) |
| Dec 2026 | [Litifilimab topline data readout](https://sec-api.dev/pdufa/litifilimab) | BIIB | Lupus Erythematosus, Systemic | scheduled | "•The Company expects to announce top line data from both TOPAZ-1 and TOPAZ-2 Phase 3 studies, evaluating litifilimab in SLE, in the first half of December 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/875045/000087504526000094/exhibit991-q32026pressrele.htm)) |
| Dec 2026 to Mar 2027 | [Imbruvica (ibrutinib) topline data readout](https://sec-api.dev/pdufa/ibrutinib) | JNJ | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Mantle Cell Lymphoma | scheduled | "NCT01804686 (A Long-term Extension Study of PCI-32765 (Ibrutinib)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT01804686)) |
| December 2026 | [XPOVIO® (selinexor) primary completion](https://sec-api.dev/pdufa/selinexor) | KPTIQ | Diffuse Large B-cell Lymphoma | scheduled | "NCT02227251 (Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Karyopharm Therapeutics Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02227251)) |
| Dec 2026 to Mar 2027 | [XPOVIO® (selinexor) topline data readout](https://sec-api.dev/pdufa/selinexor) | KPTIQ | Diffuse Large B-cell Lymphoma | scheduled | "NCT02227251 (Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Karyopharm Therapeutics Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02227251)) |
| Dec 2026 to Mar 2027 | [OJJAARA (momelotinib) topline data readout](https://sec-api.dev/pdufa/momelotinib) | GSK | Primary Myelofibrosis | scheduled | "NCT03441113 (Extended Access of Momelotinib in Adults With Myelofibrosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-11 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03441113)) |
| December 2026 | [Lifyorli™ (relacorilant) primary completion](https://sec-api.dev/pdufa/relacorilant) | CORT | Cushing Syndrome | scheduled | "NCT03604198 (Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Corcept Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03604198)) |
| Dec 2026 to Mar 2027 | [Lifyorli™ (relacorilant) topline data readout](https://sec-api.dev/pdufa/relacorilant) | CORT | Cushing Syndrome | scheduled | "NCT03604198 (Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Corcept Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03604198)) |
| December 2026 | [Ralinepag primary completion](https://sec-api.dev/pdufa/ralinepag) | UTHR | PAH; Pulmonary Hypertension; Pulmonary Arterial Hypertension | scheduled | "NCT03683186 (A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor United Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03683186)) |
| Dec 2026 to Mar 2027 | [Ralinepag topline data readout](https://sec-api.dev/pdufa/ralinepag) | UTHR | PAH; Pulmonary Hypertension; Pulmonary Arterial Hypertension | scheduled | "NCT03683186 (A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor United Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03683186)) |
| December 2026 | [Erleada (apalutamide) primary completion](https://sec-api.dev/pdufa/apalutamide) | JNJ | Prostatic Neoplasms | scheduled | "NCT03767244 (A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-01 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03767244)) |
| Dec 2026 to Mar 2027 | [Erleada (apalutamide) topline data readout](https://sec-api.dev/pdufa/apalutamide) | JNJ | Prostatic Neoplasms | scheduled | "NCT03767244 (A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-01 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03767244)) |
| December 2026 | [BRTX-100 primary completion](https://sec-api.dev/pdufa/brtx-100) | BRTX | Lumbar Disc Disease | scheduled | "NCT04042844 (A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor BioRestorative Therapies." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04042844)) |
| Dec 2026 to Mar 2027 | [BRTX-100 topline data readout](https://sec-api.dev/pdufa/brtx-100) | BRTX | Lumbar Disc Disease | scheduled | "NCT04042844 (A Single Dose of BRTX 100 for Patients With Chronic Lumbar Disc Disease (cLDD)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor BioRestorative Therapies." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04042844)) |
| Dec 2026 to Mar 2027 | [BRUKINSA® (zanubrutinib) topline data readout](https://sec-api.dev/pdufa/zanubrutinib) | ONC | B-cell Malignancies | scheduled | "NCT04170283 (A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor BeOne Medicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04170283)) |
| December 2026 | [Selinexor (combination therapy) primary completion](https://sec-api.dev/pdufa/selinexor-combination-therapy) | KPTIQ | Relapsed/Refractory Diffuse Large B-cell Lymphoma | scheduled | "NCT04442022 (A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Karyopharm Therapeutics Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04442022)) |
| Dec 2026 to Mar 2027 | [Selinexor (combination therapy) topline data readout](https://sec-api.dev/pdufa/selinexor-combination-therapy) | KPTIQ | Relapsed/Refractory Diffuse Large B-cell Lymphoma | scheduled | "NCT04442022 (A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Karyopharm Therapeutics Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04442022)) |
| Dec 2026 to Mar 2027 | [Pf-07104091 monotherapy dose escalation topline data readout](https://sec-api.dev/pdufa/pf-07104091-monotherapy) | PFE | Small Cell Lung Cancer; Ovarian Cancer; Breast Cancer | scheduled | "NCT04553133 (PF-07104091 as a Single Agent and in Combination Therapy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04553133)) |
| December 2026 | [Sacituzumab govitecan-hziy primary completion](https://sec-api.dev/pdufa/sacituzumab-govitecan-hziy) | GILD | Metastatic Breast Cancer | scheduled | "NCT04639986 (Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04639986)) |
| Dec 2026 to Mar 2027 | [Sacituzumab govitecan-hziy topline data readout](https://sec-api.dev/pdufa/sacituzumab-govitecan-hziy) | GILD | Metastatic Breast Cancer | scheduled | "NCT04639986 (Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Gilead Sciences." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04639986)) |
| Dec 2026 to Mar 2027 | [ZEJULA (niraparib) topline data readout](https://sec-api.dev/pdufa/niraparib) | GSK | Ovarian Neoplasms; Breast Neoplasms | scheduled | "NCT04641247 (A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12-28 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04641247)) |
| Dec 2026 to Mar 2027 | [Gemzar (gemcitabine) topline data readout](https://sec-api.dev/pdufa/gemcitabine) | JNJ | Urinary Bladder Neoplasms | scheduled | "NCT04658862 (A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-30 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04658862)) |
| December 2026 | [Abbv-rgx-314 dose 1 primary completion](https://sec-api.dev/pdufa/abbv-rgx-314) | ABBV | AMD; nAMD; Wet Age-related Macular Degeneration | scheduled | "NCT04704921 (Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04704921)) |
| Dec 2026 to Mar 2027 | [Abbv-rgx-314 dose 1 topline data readout](https://sec-api.dev/pdufa/abbv-rgx-314) | ABBV | AMD; nAMD; Wet Age-related Macular Degeneration | scheduled | "NCT04704921 (Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04704921)) |
| Dec 2026 to Mar 2027 | [Disitamab vedotin topline data readout](https://sec-api.dev/pdufa/disitamab-vedotin) | PFE | Urothelial Carcinoma | scheduled | "NCT04879329 (A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12-11 (ESTIMATED); Lead Sponsor Seagen, a wholly owned subsidiary of Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04879329)) |
| Dec 2026 to Mar 2027 | [Covid-19 vaccine topline data readout](https://sec-api.dev/pdufa/covid-19-vaccine) | GOVX | COVID-19 Infection; Hematopoietic and Lymphoid System Neoplasm; Leukemia | scheduled | "NCT04977024 (SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor GeoVax, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04977024)) |
| Dec 2026 to Mar 2027 | [NEO100 (NEO100) topline data readout](https://sec-api.dev/pdufa/neo100) | NTHI | Residual, Progressive or Recurrent Grade II or III Meningioma | scheduled | "NCT05023018 (NEO100 and High-Grade Meningioma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12-30 (ESTIMATED); Lead Sponsor Neonc Technologies, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05023018)) |
| Dec 2026 to Mar 2027 | [Talzenna (talazoparib tosylate) topline data readout](https://sec-api.dev/pdufa/talazoparib) | PFE | Advanced Malignancies; NSCLC; Ovarian Cancer | scheduled | "NCT05059522 (Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05059522)) |
| December 2026 | [Recombinant human tissue kallikrein primary completion](https://sec-api.dev/pdufa/recombinant-human-tissue-kallikrein) | DMAC | Acute Stroke; Ischemic Stroke; Stroke | scheduled | "NCT05065216 (Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor DiaMedica Therapeutics Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05065216)) |
| Dec 2026 to Mar 2027 | [Recombinant human tissue kallikrein topline data readout](https://sec-api.dev/pdufa/recombinant-human-tissue-kallikrein) | DMAC | Acute Stroke; Ischemic Stroke; Stroke | scheduled | "NCT05065216 (Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor DiaMedica Therapeutics Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05065216)) |
| December 2026 | [APG2575 primary completion](https://sec-api.dev/pdufa/apg2575) | AAPG | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma | scheduled | "NCT05147467 (Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Ascentage Pharma Group Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05147467)) |
| Dec 2026 to Mar 2027 | [APG2575 topline data readout](https://sec-api.dev/pdufa/apg2575) | AAPG | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma | scheduled | "NCT05147467 (Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Ascentage Pharma Group Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05147467)) |
| December 2026 | [Olvimulogene nanivacirepvec primary completion](https://sec-api.dev/pdufa/olvimulogene-nanivacirepvec) | GNLX |  | scheduled | "NCT05281471 (Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Genelux Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05281471)) |
| Dec 2026 to Mar 2027 | [Olvimulogene nanivacirepvec topline data readout](https://sec-api.dev/pdufa/olvimulogene-nanivacirepvec) | GNLX |  | scheduled | "NCT05281471 (Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Genelux Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05281471)) |
| Dec 2026 to Mar 2027 | [Imfinzi® (durvalumab) topline data readout](https://sec-api.dev/pdufa/durvalumab) | AZN | Cancer | scheduled | "NCT05303532 (Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05303532)) |
| Dec 2026 to Mar 2027 | [IMAAVY (nipocalimab) topline data readout](https://sec-api.dev/pdufa/nipocalimab) | JNJ | Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | scheduled | "NCT05327114 (Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2026-12-15 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05327114)) |
| December 2026 | [DAWNZERA™ (donidalorsen) primary completion](https://sec-api.dev/pdufa/donidalorsen) | IONS | Hereditary Angioedema | scheduled | "NCT05392114 (A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Ionis Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05392114)) |
| Dec 2026 to Mar 2027 | [DAWNZERA™ (donidalorsen) topline data readout](https://sec-api.dev/pdufa/donidalorsen) | IONS | Hereditary Angioedema | scheduled | "NCT05392114 (A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Ionis Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05392114)) |
| December 2026 | [Anitocabtagene autoleucel primary completion](https://sec-api.dev/pdufa/anitocabtagene-autoleucel) | GILD | Multiple Myeloma | scheduled | "NCT05396885 (Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Kite, A Gilead Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05396885)) |
| Dec 2026 to Mar 2027 | [Anitocabtagene autoleucel topline data readout](https://sec-api.dev/pdufa/anitocabtagene-autoleucel) | GILD | Multiple Myeloma | scheduled | "NCT05396885 (Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Kite, A Gilead Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05396885)) |
| December 2026 | [Tavocept primary completion](https://sec-api.dev/pdufa/tavocept) | LTRN | Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung | scheduled | "NCT05456256 (A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Lantern Pharma Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05456256)) |
| Dec 2026 to Mar 2027 | [Tavocept topline data readout](https://sec-api.dev/pdufa/tavocept) | LTRN | Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung | scheduled | "NCT05456256 (A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Lantern Pharma Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05456256)) |
| Dec 2026 to Mar 2027 | [MN-001 topline data readout](https://sec-api.dev/pdufa/mn-001) | MNOV | Diabetes Mellitus, Type 2; Hypertriglyceridemia; Non-Alcoholic Fatty Liver Disease | scheduled | "NCT05464784 (MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor MediciNova." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05464784)) |
| December 2026 | [Rezdiffra (resmetirom) primary completion](https://sec-api.dev/pdufa/resmetirom) | MDGL | NASH; Cirrhosis, Liver | scheduled | "NCT05500222 (A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Madrigal Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05500222)) |
| Dec 2026 to Mar 2027 | [Rezdiffra (resmetirom) topline data readout](https://sec-api.dev/pdufa/resmetirom) | MDGL | NASH; Cirrhosis, Liver | scheduled | "NCT05500222 (A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Madrigal Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05500222)) |
| Dec 2026 to Mar 2027 | [Treprostinil palmitil topline data readout](https://sec-api.dev/pdufa/treprostinil-palmitil) | INSM | Pulmonary Arterial Hypertension | scheduled | "NCT05649748 (An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor Insmed Incorporated." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05649748)) |
| Dec 2026 to Mar 2027 | [Cenerimod 4 mg topline data readout](https://sec-api.dev/pdufa/cenerimod) | VTRS | Lupus Erythematosus, Systemic | scheduled | "NCT05672576 (A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor Viatris Innovation GmbH." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05672576)) |
| Dec 2026 to Mar 2027 | [XL092 topline data readout](https://sec-api.dev/pdufa/xl092) | EXEL | Non-Clear Cell Renal Cell Carcinoma | scheduled | "NCT05678673 (Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-15 (ESTIMATED); Lead Sponsor Exelixis." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05678673)) |
| Dec 2026 to Mar 2027 | [Fasenra (benralizumab) topline data readout](https://sec-api.dev/pdufa/benralizumab) | AZN | Asthma | scheduled | "NCT05692180 (A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-23 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05692180)) |
| Dec 2026 to Mar 2027 | [Milvexian topline data readout](https://sec-api.dev/pdufa/milvexian) | JNJ | Atrial Fibrillation | scheduled | "NCT05757869 (A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-08 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05757869)) |
| Dec 2026 to Mar 2027 | [Qrx003, 4% lotion topline data readout](https://sec-api.dev/pdufa/qrx003-4-lotion) | QNRX | Netherton Syndrome | scheduled | "NCT05789056 (Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton Syndrome): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2026-12-30 (ESTIMATED); Lead Sponsor Quoin Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05789056)) |
| Dec 2026 to Mar 2027 | [AAA617 topline data readout](https://sec-api.dev/pdufa/aaa617) | NVS | Prostatic Neoplasm | scheduled | "NCT05849298 (A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-23 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05849298)) |
| December 2026 | [TARA-002 primary completion](https://sec-api.dev/pdufa/tara-002) | TARA | Lymphatic Malformation | scheduled | "NCT05871970 (Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Protara Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05871970)) |
| Dec 2026 to Mar 2027 | [TARA-002 topline data readout](https://sec-api.dev/pdufa/tara-002) | TARA | Lymphatic Malformation | scheduled | "NCT05871970 (Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Protara Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05871970)) |
| Dec 2026 to Mar 2027 | [IBRANCE® (palbociclib) topline data readout](https://sec-api.dev/pdufa/palbociclib) | PFE | Breast Cancer | scheduled | "NCT05909397 (Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-30 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05909397)) |
| December 2026 | [ALTO-300 primary completion](https://sec-api.dev/pdufa/alto-300) | ANRO | Major Depressive Disorder | scheduled | "NCT05922878 (Study of ALTO-300 in MDD): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Alto Neuroscience." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05922878)) |
| Dec 2026 to Mar 2027 | [ALTO-300 topline data readout](https://sec-api.dev/pdufa/alto-300) | ANRO | Major Depressive Disorder | scheduled | "NCT05922878 (Study of ALTO-300 in MDD): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Alto Neuroscience." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05922878)) |
| December 2026 | [Descartes-08 primary completion](https://sec-api.dev/pdufa/descartes-08) | RNAC | Systemic Lupus Erythematosus (SLE) | scheduled | "NCT06038474 (Descartes-08 for Patients With Systemic Lupus Erythematosus): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-01 (ESTIMATED); Lead Sponsor Cartesian Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06038474)) |
| Dec 2026 to Mar 2027 | [Descartes-08 topline data readout](https://sec-api.dev/pdufa/descartes-08) | RNAC | Systemic Lupus Erythematosus (SLE) | scheduled | "NCT06038474 (Descartes-08 for Patients With Systemic Lupus Erythematosus): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-01 (ESTIMATED); Lead Sponsor Cartesian Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06038474)) |
| Dec 2026 to Mar 2027 | [TEV-56248 topline data readout](https://sec-api.dev/pdufa/tev-56248) | TEVA | Asthma | scheduled | "NCT06052267 (A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor Teva Branded Pharmaceutical Products R&D LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06052267)) |
| Dec 2026 to Mar 2027 | [Lisaftoclax +btk inhibitor topline data readout](https://sec-api.dev/pdufa/lisaftoclax-btk-inhibitor) | AAPG | CLL/SLL | scheduled | "NCT06104566 (Global Trial in APG2575 for Patients With CLL/SLL): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor Ascentage Pharma Group Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06104566)) |
| December 2026 | [ABBV-400 primary completion](https://sec-api.dev/pdufa/abbv-400) | ABBV | Unresectable Metastatic Colorectal Cancer | scheduled | "NCT06107413 (Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06107413)) |
| Dec 2026 to Mar 2027 | [ABBV-400 topline data readout](https://sec-api.dev/pdufa/abbv-400) | ABBV | Unresectable Metastatic Colorectal Cancer | scheduled | "NCT06107413 (Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06107413)) |
| Dec 2026 to Mar 2027 | [BMS-986435 topline data readout](https://sec-api.dev/pdufa/bms-986435) | BMY | Heart Failure | scheduled | "NCT06122779 (Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-14 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06122779)) |
| Dec 2026 to Mar 2027 | [Karxt topline data readout](https://sec-api.dev/pdufa/karxt) | BMY | Psychosis Associated With Alzheimer's Disease | scheduled | "NCT06126224 (A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12-09 (ESTIMATED); Lead Sponsor Karuna Therapeutics, Inc., a Bristol Myers Squibb company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06126224)) |
| December 2026 | [BHV-7000 primary completion](https://sec-api.dev/pdufa/bhv-7000) | BHVN | Focal Epilepsy | scheduled | "NCT06132893 (A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Biohaven Therapeutics Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06132893)) |
| Dec 2026 to Mar 2027 | [BHV-7000 topline data readout](https://sec-api.dev/pdufa/bhv-7000) | BHVN | Focal Epilepsy | scheduled | "NCT06132893 (A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Biohaven Therapeutics Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06132893)) |
| Dec 2026 to Mar 2027 | [Povofortay (povorcitinib) topline data readout](https://sec-api.dev/pdufa/povorcitinib) | INCY | Hidradenitis Suppurativa (HS) | scheduled | "NCT06212999 (A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-26 (ESTIMATED); Lead Sponsor Incyte Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06212999)) |
| December 2026 | [EIK1001 primary completion](https://sec-api.dev/pdufa/eik1001) | EIKN | NSCLC | scheduled | "NCT06246110 (A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Eikon Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06246110)) |
| Dec 2026 to Mar 2027 | [EIK1001 topline data readout](https://sec-api.dev/pdufa/eik1001) | EIKN | NSCLC | scheduled | "NCT06246110 (A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Eikon Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06246110)) |
| Dec 2026 to Mar 2027 | [BMS-986446 topline data readout](https://sec-api.dev/pdufa/bms-986446) | BMY | Alzheimer Disease, Early Onset | scheduled | "NCT06268886 (Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-17 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06268886)) |
| December 2026 | [Zilretta primary completion](https://sec-api.dev/pdufa/zilretta) | PCRX | Glenohumeral Osteoarthritis | scheduled | "NCT06269705 (ZILRETTA in Subjects With Shoulder Osteoarthritis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Pacira Pharmaceuticals, Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06269705)) |
| Dec 2026 to Mar 2027 | [Zilretta topline data readout](https://sec-api.dev/pdufa/zilretta) | PCRX | Glenohumeral Osteoarthritis | scheduled | "NCT06269705 (ZILRETTA in Subjects With Shoulder Osteoarthritis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Pacira Pharmaceuticals, Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06269705)) |
| December 2026 | [Seralutinib primary completion](https://sec-api.dev/pdufa/seralutinib) | GOSS | Pulmonary Arterial Hypertension | scheduled | "NCT06274801 (Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Gossamer Bio USA, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06274801)) |
| Dec 2026 to Mar 2027 | [Seralutinib topline data readout](https://sec-api.dev/pdufa/seralutinib) | GOSS | Pulmonary Arterial Hypertension | scheduled | "NCT06274801 (Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Gossamer Bio USA, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06274801)) |
| December 2026 | [Oms906 study drug primary completion](https://sec-api.dev/pdufa/oms906-study-drug) | OMER | Paroxysmal Nocturnal Hemoglobinuria | scheduled | "NCT06298955 (Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Omeros Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06298955)) |
| Dec 2026 to Mar 2027 | [Oms906 study drug topline data readout](https://sec-api.dev/pdufa/oms906-study-drug) | OMER | Paroxysmal Nocturnal Hemoglobinuria | scheduled | "NCT06298955 (Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Omeros Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06298955)) |
| Dec 2026 to Mar 2027 | [Jemperli (dostarlimab) topline data readout](https://sec-api.dev/pdufa/dostarlimab) | GSK | Carcinoma | scheduled | "NCT06317311 (A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-14 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06317311)) |
| Dec 2026 to Mar 2027 | [FABHALTA® (iptacopan) topline data readout](https://sec-api.dev/pdufa/iptacopan) | NVS | Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis | scheduled | "NCT06388941 (Iptacopan in Patients With ANCA Associated Vasculitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-30 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06388941)) |
| December 2026 | [SUNOSI® (solriamfetol) primary completion](https://sec-api.dev/pdufa/solriamfetol) | AXSM | Binge-Eating Disorder | scheduled | "NCT06413433 (Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Axsome Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06413433)) |
| Dec 2026 to Mar 2027 | [REGN7999 topline data readout](https://sec-api.dev/pdufa/regn7999) | REGN | Non-Transfusion Dependent Beta-Thalassemia (NTDT) | scheduled | "NCT06421636 (A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-03 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06421636)) |
| Dec 2026 to Mar 2027 | [ABP-234 topline data readout](https://sec-api.dev/pdufa/abp-234) | AMGN | Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC) | scheduled | "NCT06430866 (Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-14 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06430866)) |
| December 2026 | [BHV-7000 primary completion](https://sec-api.dev/pdufa/bhv-7000) | BHVN | Focal Epilepsy | scheduled | "NCT06443463 (Long-term Safety and Tolerability of BHV-7000): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Biohaven Therapeutics Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06443463)) |
| Dec 2026 to Mar 2027 | [BHV-7000 topline data readout](https://sec-api.dev/pdufa/bhv-7000) | BHVN | Focal Epilepsy | scheduled | "NCT06443463 (Long-term Safety and Tolerability of BHV-7000): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Biohaven Therapeutics Ltd.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06443463)) |
| December 2026 | [Obefazimod primary completion](https://sec-api.dev/pdufa/obefazimod) | ABVX | Moderately to Severely Active Crohn Disease | scheduled | "NCT06456593 (Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Abivax S.A.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06456593)) |
| December 2026 | [Lutikizumab primary completion](https://sec-api.dev/pdufa/lutikizumab) | ABBV | Hidradenitis Suppurativa | scheduled | "NCT06468228 (A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06468228)) |
| Dec 2026 to Mar 2027 | [Lutikizumab topline data readout](https://sec-api.dev/pdufa/lutikizumab) | ABBV | Hidradenitis Suppurativa | scheduled | "NCT06468228 (A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor AbbVie." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06468228)) |
| Dec 2026 to Mar 2027 | [Wayrilz (rilzabrutinib) topline data readout](https://sec-api.dev/pdufa/rilzabrutinib) | SNY | Focal Segmental Glomerulosclerosis; Glomerulonephritis Minimal Lesion | scheduled | "NCT06500702 (A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12-23 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06500702)) |
| December 2026 | [Claseprubart primary completion](https://sec-api.dev/pdufa/claseprubart) | DNTH | Multifocal Motor Neuropathy | scheduled | "NCT06537999 (A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Dianthus Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06537999)) |
| Dec 2026 to Mar 2027 | [JNJ-64042056 topline data readout](https://sec-api.dev/pdufa/jnj-64042056) | JNJ | Alzheimer Disease | scheduled | "NCT06544616 (A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-22 (ESTIMATED); Lead Sponsor Janssen Pharmaceutica N.V., Belgium." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06544616)) |
| Dec 2026 to Mar 2027 | [Seltorexant topline data readout](https://sec-api.dev/pdufa/seltorexant) | JNJ | Depressive Disorder, Major | scheduled | "NCT06559306 (Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12-30 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06559306)) |
| December 2026 | [SUNOSI® (solriamfetol) primary completion](https://sec-api.dev/pdufa/solriamfetol) | AXSM | Excessive Sleepiness; Shift-work Disorder | scheduled | "NCT06568367 (Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Axsome Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06568367)) |
| December 2026 | [Escharex (ex-03) primary completion](https://sec-api.dev/pdufa/escharex-ex-03) | MDWD | Venous Leg Ulcer (VLU) | scheduled | "NCT06568627 (A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor MediWound Ltd." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06568627)) |
| Dec 2026 to Mar 2027 | [Escharex (ex-03) topline data readout](https://sec-api.dev/pdufa/escharex-ex-03) | MDWD | Venous Leg Ulcer (VLU) | scheduled | "NCT06568627 (A Double Blind Study Performed to Evaluate the Efficacy and the Safety of EscharEx in Debridement of VLU (VALUE)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor MediWound Ltd." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06568627)) |
| December 2026 | [Melphalan/hds followed by consolidation treatment with trifluridine-tipiracil plus bevacizumab primary completion](https://sec-api.dev/pdufa/melphalan-hds-followed-by-consolidation-treatment-with-trifluridine-tipiracil-pl) | DCTH | Refractory Metastatic Colorectal Cancer | scheduled | "NCT06607458 (Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Delcath Systems Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06607458)) |
| Dec 2026 to Mar 2027 | [Melphalan/hds followed by consolidation treatment with trifluridine-tipiracil plus bevacizumab topline data readout](https://sec-api.dev/pdufa/melphalan-hds-followed-by-consolidation-treatment-with-trifluridine-tipiracil-pl) | DCTH | Refractory Metastatic Colorectal Cancer | scheduled | "NCT06607458 (Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Delcath Systems Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06607458)) |
| Dec 2026 to Mar 2027 | [Gefurulimab topline data readout](https://sec-api.dev/pdufa/gefurulimab) | AZN | Generalized Myasthenia Gravis; gMG | scheduled | "NCT06607627 (PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12-15 (ESTIMATED); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06607627)) |
| December 2026 | [Felzartamab primary completion](https://sec-api.dev/pdufa/felzartamab) | BIIB | Antibody-mediated Rejection | scheduled | "NCT06685757 (A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-01 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06685757)) |
| Dec 2026 to Mar 2027 | [Felzartamab topline data readout](https://sec-api.dev/pdufa/felzartamab) | BIIB | Antibody-mediated Rejection | scheduled | "NCT06685757 (A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-01 (ESTIMATED); Lead Sponsor Biogen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06685757)) |
| Dec 2026 to Mar 2027 | [Ziihera® (zanidatamab) topline data readout](https://sec-api.dev/pdufa/zanidatamab) | JAZZ | Breast Cancer; Gastric Cancer; Esophageal Cancer | scheduled | "NCT06695845 (A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor Jazz Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06695845)) |
| Dec 2026 to Mar 2027 | [Soliris (eculizumab) topline data readout](https://sec-api.dev/pdufa/eculizumab) | AZN | NMOSD; Neuromyelitis Optica Spectrum Disorders | scheduled | "NCT06724809 (Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-07 (ESTIMATED); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06724809)) |
| Dec 2026 to Mar 2027 | [PCV-20 topline data readout](https://sec-api.dev/pdufa/pcv-20) | GSK | Chickenpox | scheduled | "NCT06740630 (A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12-25 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06740630)) |
| Dec 2026 to Mar 2027 | [Decartes-08 topline data readout](https://sec-api.dev/pdufa/decartes-08) | RNAC | Myasthaenia Gravis | scheduled | "NCT06799247 (Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-30 (ESTIMATED); Lead Sponsor Cartesian Therapeutics." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06799247)) |
| Dec 2026 to Mar 2027 | [PCV-20 topline data readout](https://sec-api.dev/pdufa/pcv-20) | GSK | Chickenpox | scheduled | "NCT06806137 (A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12-14 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06806137)) |
| December 2026 | [PCV21 primary completion](https://sec-api.dev/pdufa/pcv21) | SNY | Pneumococcal Infections | scheduled | "NCT06838000 (Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-01 (ESTIMATED); Lead Sponsor Sanofi Pasteur, a Sanofi Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06838000)) |
| Dec 2026 to Mar 2027 | [PCV21 topline data readout](https://sec-api.dev/pdufa/pcv21) | SNY | Pneumococcal Infections | scheduled | "NCT06838000 (Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-01 (ESTIMATED); Lead Sponsor Sanofi Pasteur, a Sanofi Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06838000)) |
| December 2026 | [Halneuron (halneuron) primary completion](https://sec-api.dev/pdufa/halneuron) | DWTX |  | scheduled | "NCT06848348 (Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Dogwood Therapeutics Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06848348)) |
| Dec 2026 to Mar 2027 | [Halneuron (halneuron) topline data readout](https://sec-api.dev/pdufa/halneuron) | DWTX |  | scheduled | "NCT06848348 (Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Dogwood Therapeutics Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06848348)) |
| Dec 2026 to Mar 2027 | [Qrx003, 4% lotion topline data readout](https://sec-api.dev/pdufa/qrx003-4-lotion) | QNRX | Netherton Syndrome | scheduled | "NCT06953466 (Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2026-12-30 (ESTIMATED); Lead Sponsor Quoin Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06953466)) |
| Dec 2026 to Mar 2027 | [Brivekimig topline data readout](https://sec-api.dev/pdufa/brivekimig) | SNY | Crohn's Disease | scheduled | "NCT06958536 (A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12-17 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06958536)) |
| December 2026 | [VDPHL01 primary completion](https://sec-api.dev/pdufa/vdphl01) | MANE | Androgenetic Alopecia; AGA; Male Pattern Baldness | scheduled | "NCT06972264 (Safety and Efficacy of VDPHL01 in Males With AGA): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Veradermics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06972264)) |
| Dec 2026 to Mar 2027 | [VDPHL01 topline data readout](https://sec-api.dev/pdufa/vdphl01) | MANE | Androgenetic Alopecia; AGA; Male Pattern Baldness | scheduled | "NCT06972264 (Safety and Efficacy of VDPHL01 in Males With AGA): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Veradermics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06972264)) |
| Dec 2026 to Mar 2027 | [Brivekimig topline data readout](https://sec-api.dev/pdufa/brivekimig) | SNY | Ulcerative Colitis | scheduled | "NCT06975722 (A Study to Investigate the Efficacy and Safety of Brivekimig in Adult Participants With Ulcerative Colitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-17 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06975722)) |
| Dec 2026 to Mar 2027 | [Luxdegalutamide topline data readout](https://sec-api.dev/pdufa/luxdegalutamide) | NVS | Metastatic Hormone-sensitive Prostate Cancer | scheduled | "NCT06991556 (An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-03 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06991556)) |
| December 2026 | [Praxis Precision Medicines, Inc. primary completion](https://sec-api.dev/companies/prax/catalysts) | PRAX | Developmental and Epileptic Encephalopathy 1 | scheduled | "NCT07010471 (A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Praxis Precision Medicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07010471)) |
| Dec 2026 to Mar 2027 | [Praxis Precision Medicines, Inc. topline data readout](https://sec-api.dev/companies/prax/catalysts) | PRAX | Developmental and Epileptic Encephalopathy 1 | scheduled | "NCT07010471 (A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Praxis Precision Medicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07010471)) |
| Dec 2026 to Mar 2027 | [CERUS CORP topline data readout](https://sec-api.dev/companies/cers/catalysts) | CERS | Healthy Subjects | scheduled | "NCT07015437 (A Recovery and Lifespan Study Using INTERCEPT Red Blood Cells Prepared Using the INTERCEPT Blood System for RBCs With AS-1): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12-15 (ESTIMATED); Lead Sponsor Cerus Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07015437)) |
| December 2026 | [KB803 primary completion](https://sec-api.dev/pdufa/kb803) | KRYS |  | scheduled | "NCT07016750 (A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Krystal Biotech, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07016750)) |
| December 2026 | [Praxis Precision Medicines, Inc. primary completion](https://sec-api.dev/companies/prax/catalysts) | PRAX | Epileptic Encephalopathy; SCN2A Encephalopathy | scheduled | "NCT07019922 (A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Praxis Precision Medicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07019922)) |
| Dec 2026 to Mar 2027 | [Praxis Precision Medicines, Inc. topline data readout](https://sec-api.dev/companies/prax/catalysts) | PRAX | Epileptic Encephalopathy; SCN2A Encephalopathy | scheduled | "NCT07019922 (A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Praxis Precision Medicines." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07019922)) |
| Dec 2026 to Mar 2027 | [Ritlecitinib higher dose topline data readout](https://sec-api.dev/pdufa/ritlecitinib-higher-dose) | PFE | Severe Alopecia Areata | scheduled | "NCT07029711 (A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-02 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07029711)) |
| December 2026 | [Bemnifosbuvir-ruzasvir primary completion](https://sec-api.dev/pdufa/bemnifosbuvir-ruzasvir) | AVIR | HEPATITIS C VIRUS CHRONIC INFECTION; Hepatitis C, Chronic; Hepatitis C Virus Infection | scheduled | "NCT07037277 (C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Atea Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07037277)) |
| Dec 2026 to Mar 2027 | [Bemnifosbuvir-ruzasvir topline data readout](https://sec-api.dev/pdufa/bemnifosbuvir-ruzasvir) | AVIR | HEPATITIS C VIRUS CHRONIC INFECTION; Hepatitis C, Chronic; Hepatitis C Virus Infection | scheduled | "NCT07037277 (C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Atea Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07037277)) |
| Dec 2026 to Mar 2027 | [Rabies vaccine (serum-free vero cell), freeze-dried topline data readout](https://sec-api.dev/pdufa/rabies-vaccine-serum-free-vero-cell-freeze-dried) | SVA | Rabies | scheduled | "NCT07055295 (Immunogenicity and Safety of Rabies Vaccine (Serum-free Vero Cell) in a Pre-exposure Prophylaxis Regimen): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2026-12-30 (ESTIMATED); Lead Sponsor Sinovac Biotech Co., Ltd." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07055295)) |
| December 2026 | [Tobevibart primary completion](https://sec-api.dev/pdufa/tobevibart) | VIR | Viral Hepatitis | scheduled | "NCT07128550 (A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Vir Biotechnology, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07128550)) |
| Dec 2026 to Mar 2027 | [Tobevibart topline data readout](https://sec-api.dev/pdufa/tobevibart) | VIR | Viral Hepatitis | scheduled | "NCT07128550 (A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Vir Biotechnology, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07128550)) |
| December 2026 | [LY3537021 primary completion](https://sec-api.dev/pdufa/ly3537021) | LLY | Nausea; Vomiting; Drug-Related Side Effects and Adverse Reactions | scheduled | "NCT07169851 (A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07169851)) |
| Dec 2026 to Mar 2027 | [LY3537021 topline data readout](https://sec-api.dev/pdufa/ly3537021) | LLY | Nausea; Vomiting; Drug-Related Side Effects and Adverse Reactions | scheduled | "NCT07169851 (A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Eli Lilly and Company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07169851)) |
| Dec 2026 to Mar 2027 | [NNC0662-0419 topline data readout](https://sec-api.dev/pdufa/nnc0662-0419) | NVO | Overweight; Obesity | scheduled | "NCT07184632 (A Research Study on How Well Different Doses of the Medicine NNC0662-0419 Help People Living With Overweight or Obesity): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-14 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07184632)) |
| December 2026 | [AP02 primary completion](https://sec-api.dev/pdufa/ap02) | AVLN | Idiopathic Pulmonary Fibrosis (IPF) | scheduled | "NCT07194382 (AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Avalyn Pharma Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07194382)) |
| Dec 2026 to Mar 2027 | [AP02 topline data readout](https://sec-api.dev/pdufa/ap02) | AVLN | Idiopathic Pulmonary Fibrosis (IPF) | scheduled | "NCT07194382 (AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Avalyn Pharma Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07194382)) |
| Dec 2026 to Mar 2027 | [Litfulo (ritlecitinib tosylate) topline data readout](https://sec-api.dev/pdufa/ritlecitinib) | PFE | Chronic Spontaneous Urticaria | scheduled | "NCT07219615 (A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12-25 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07219615)) |
| December 2026 | [VQW-765 primary completion](https://sec-api.dev/pdufa/vqw-765) | VNDA | Social Anxiety Disorder (SAD) | scheduled | "NCT07221578 (Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Vanda Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07221578)) |
| Dec 2026 to Mar 2027 | [VQW-765 topline data readout](https://sec-api.dev/pdufa/vqw-765) | VNDA | Social Anxiety Disorder (SAD) | scheduled | "NCT07221578 (Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Vanda Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07221578)) |
| Dec 2026 to Mar 2027 | [Baxdrostat/dapagliflozin topline data readout](https://sec-api.dev/pdufa/baxdrostat-dapagliflozin) | AZN | Chronic Kidney Disease and Hypertension | scheduled | "NCT07222917 (A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-10 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07222917)) |
| Dec 2026 to Mar 2027 | [Spn-821 2400 mg topline data readout](https://sec-api.dev/pdufa/spn-821) | SUPN | Major Depressive Disorder (MDD) | scheduled | "NCT07226661 (Double-blind, Placebo-controlled Study in Adults With Major Depressive Disorder): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor Supernus Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07226661)) |
| Dec 2026 to Mar 2027 | [Litfulo (ritlecitinib tosylate) topline data readout](https://sec-api.dev/pdufa/ritlecitinib) | PFE | Hidradenitis Suppurativa | scheduled | "NCT07228390 (A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-08 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07228390)) |
| Dec 2026 to Mar 2027 | [TAK-861 topline data readout](https://sec-api.dev/pdufa/tak-861) | TAK | Narcolepsy Type 1 (NT1); Narcolepsy With Cataplexy | scheduled | "NCT07363720 (A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-17 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07363720)) |
| December 2026 | [TRX-100 primary completion](https://sec-api.dev/pdufa/trx-100) | TRAW | Influenza | scheduled | "NCT07371650 (This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Tivoxavir Marboxil in Patients With Mild to Moderate Influenza): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Traws Pharma, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07371650)) |
| Dec 2026 to Mar 2027 | [TRX-100 topline data readout](https://sec-api.dev/pdufa/trx-100) | TRAW | Influenza | scheduled | "NCT07371650 (This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Tivoxavir Marboxil in Patients With Mild to Moderate Influenza): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Traws Pharma, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07371650)) |
| Dec 2026 to Mar 2027 | [Xdemvy (lotilaner) topline data readout](https://sec-api.dev/pdufa/lotilaner) | TARS | Ocular Rosacea | scheduled | "NCT07443202 (Study of Lotilaner Ophthalmic Gel in Patients With Ocular Rosacea (KORE)): Overall Status ENROLLING_BY_INVITATION; Phase PHASE2; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor Tarsus Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07443202)) |
| December 2026 | [NEREUSTM (tradipitant) primary completion](https://sec-api.dev/pdufa/tradipitant) | VNDA | Nausea and Vomiting; Obesity | scheduled | "NCT07446439 (A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12-01 (ESTIMATED); Lead Sponsor Vanda Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07446439)) |
| Dec 2026 to Mar 2027 | [NEREUSTM (tradipitant) topline data readout](https://sec-api.dev/pdufa/tradipitant) | VNDA | Nausea and Vomiting; Obesity | scheduled | "NCT07446439 (A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12-01 (ESTIMATED); Lead Sponsor Vanda Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07446439)) |
| Dec 2026 to Mar 2027 | [Praluent (alirocumab) topline data readout](https://sec-api.dev/pdufa/alirocumab) | REGN | Hypercholesterolemia | scheduled | "NCT07477704 (A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-29 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07477704)) |
| December 2026 | [Zelicapavir primary completion](https://sec-api.dev/pdufa/zelicapavir) | ENTA | RSV Infection; RSV; Respiratory Syncytial Virus (RSV) | scheduled | "NCT07482657 (A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Enanta Pharmaceuticals, Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07482657)) |
| Dec 2026 to Mar 2027 | [Zelicapavir topline data readout](https://sec-api.dev/pdufa/zelicapavir) | ENTA | RSV Infection; RSV; Respiratory Syncytial Virus (RSV) | scheduled | "On Track to Initiate RESOLVE, a Registrational Phase 2b/3 High-Risk Adult Trial of Zelicapavir in 4Q 2026; Topline Phase 2b Data Expected in 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1177648/000119312526342336/enta-ex99_1.htm)) |
| Dec 2026 to Mar 2027 | [VLA15 topline data readout](https://sec-api.dev/pdufa/vla15) | PFE | Lyme Disease | scheduled | "NCT07500506 (A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12-04 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07500506)) |
| December 2026 | [Tonlamarsen primary completion](https://sec-api.dev/pdufa/tonlamarsen) | KARD | Hypertension; Acute Severe Hypertension; Hypertensive Emergency | scheduled | "NCT07511361 (Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Kardigan, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07511361)) |
| Dec 2026 to Mar 2027 | [Tonlamarsen topline data readout](https://sec-api.dev/pdufa/tonlamarsen) | KARD | Hypertension; Acute Severe Hypertension; Hypertensive Emergency | scheduled | "NCT07511361 (Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Kardigan, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07511361)) |
| December 2026 | [Licaminlimab primary completion](https://sec-api.dev/pdufa/licaminlimab) | OCS | Dry Eye Disease (DED) | scheduled | "NCT07548632 (A Clinical Study Evaluating Licaminlimab for Dry Eye Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Oculis." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07548632)) |
| Dec 2026 to Mar 2027 | [HFA-152A topline data readout](https://sec-api.dev/pdufa/hfa-152a) | GSK | Asthma | scheduled | "NCT07645248 (A Study to Compare Safety of 4 Weeks Exposure to Propellants Hydrofluoroalkane 1,1-difluoroethane (HFA-152a) and HFA-1,1,1,2-tetrafluoroethane (134a)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12-28 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07645248)) |
| December 2026 | [Triesence (triamcinolone acetonide injectable suspension) primary completion](https://sec-api.dev/pdufa/triesence-triamcinolone-acetonide-injectable-suspension) | HROW | Postoperative Ocular Inflammation; Postoperative Ocular Pain | scheduled | "NCT07832552 (A Phase 3 Study Evaluating the Safety and Efficacy of TRIESENCE® (Injectable Suspension) for the Treatment of Ocular Inflammation and Pain After Ophthalmic Surgery): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Harrow Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07832552)) |
| Dec 2026 to Mar 2027 | [Triesence (triamcinolone acetonide injectable suspension) topline data readout](https://sec-api.dev/pdufa/triesence-triamcinolone-acetonide-injectable-suspension) | HROW | Postoperative Ocular Inflammation; Postoperative Ocular Pain | scheduled | "NCT07832552 (A Phase 3 Study Evaluating the Safety and Efficacy of TRIESENCE® (Injectable Suspension) for the Treatment of Ocular Inflammation and Pain After Ophthalmic Surgery): Overall Status ENROLLING_BY_INVITATION; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Harrow Inc." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07832552)) |
| December 2026 | [Tti-0102 (cysteamine-pantetheine disulfide) primary completion](https://sec-api.dev/pdufa/tti-0102-cysteamine-pantetheine-disulfide) | TTIPF | Nephropathic Cystinosis; Cystinosis | scheduled | "NCT07837726 (Pilot Study of TTI-0102 in Cystinosis): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Thiogenesis Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07837726)) |
| Dec 2026 to Mar 2027 | [Tti-0102 (cysteamine-pantetheine disulfide) topline data readout](https://sec-api.dev/pdufa/tti-0102-cysteamine-pantetheine-disulfide) | TTIPF | Nephropathic Cystinosis; Cystinosis | scheduled | "NCT07837726 (Pilot Study of TTI-0102 in Cystinosis): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Thiogenesis Therapeutics, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07837726)) |
| December 2026 | [Ritlecitinib higher dose primary completion](https://sec-api.dev/pdufa/ritlecitinib-higher-dose) | PFE | Severe Alopecia Areata | scheduled | "NCT07029711 (A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-02 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07029711)) |
| December 3, 2026 | [Zanzalintinib PDUFA date](https://sec-api.dev/pdufa/zanzalintinib) | EXEL | previously treated metastatic colorectal cancer | scheduled | ""Our first New Drug Application for zanzalintinib, for its initial potential indication in previously treated metastatic colorectal cancer, was accepted by U.S. regulatory authorities and is under active review, with a target action date of December 3, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/939767/000093976726000058/exel20260331exhibit991.htm)) |
| December 2026 | [REGN7999 primary completion](https://sec-api.dev/pdufa/regn7999) | REGN | Non-Transfusion Dependent Beta-Thalassemia (NTDT) | scheduled | "NCT06421636 (A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-03 (ESTIMATED); Lead Sponsor Regeneron Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06421636)) |
| December 2026 | [Luxdegalutamide primary completion](https://sec-api.dev/pdufa/luxdegalutamide) | NVS | Metastatic Hormone-sensitive Prostate Cancer | scheduled | "NCT06991556 (An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-03 (ESTIMATED); Lead Sponsor Novartis Pharmaceuticals." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06991556)) |
| December 2026 | [VLA15 primary completion](https://sec-api.dev/pdufa/vla15) | PFE | Lyme Disease | scheduled | "NCT07500506 (A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12-04 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07500506)) |
| December 2026 | [Soliris (eculizumab) primary completion](https://sec-api.dev/pdufa/eculizumab) | AZN | NMOSD; Neuromyelitis Optica Spectrum Disorders | scheduled | "NCT06724809 (Efficacy, Safety, PK, PD, and ADA of Eculizumab in Chinese Adults With NMOSD): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-07 (ESTIMATED); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06724809)) |
| December 2026 | [Milvexian primary completion](https://sec-api.dev/pdufa/milvexian) | JNJ | Atrial Fibrillation | scheduled | "NCT05757869 (A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-08 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05757869)) |
| December 2026 | [Litfulo (ritlecitinib tosylate) primary completion](https://sec-api.dev/pdufa/ritlecitinib) | PFE | Hidradenitis Suppurativa | scheduled | "NCT07228390 (A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-08 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07228390)) |
| December 2026 | [Karxt primary completion](https://sec-api.dev/pdufa/karxt) | BMY | Psychosis Associated With Alzheimer's Disease | scheduled | "NCT06126224 (A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12-09 (ESTIMATED); Lead Sponsor Karuna Therapeutics, Inc., a Bristol Myers Squibb company." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06126224)) |
| December 2026 | [Baxdrostat/dapagliflozin primary completion](https://sec-api.dev/pdufa/baxdrostat-dapagliflozin) | AZN | Chronic Kidney Disease and Hypertension | scheduled | "NCT07222917 (A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-10 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07222917)) |
| December 2026 | [OJJAARA (momelotinib) primary completion](https://sec-api.dev/pdufa/momelotinib) | GSK | Primary Myelofibrosis | scheduled | "NCT03441113 (Extended Access of Momelotinib in Adults With Myelofibrosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-11 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03441113)) |
| December 2026 | [Disitamab vedotin primary completion](https://sec-api.dev/pdufa/disitamab-vedotin) | PFE | Urothelial Carcinoma | scheduled | "NCT04879329 (A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12-11 (ESTIMATED); Lead Sponsor Seagen, a wholly owned subsidiary of Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04879329)) |
| December 12, 2026 | [Imsidolimab PDUFA date](https://sec-api.dev/pdufa/imsidolimab) | VNDA |  | scheduled | "•QuimilzaTM (imsidolimab) BLA for GPP under review by the FDA; PDUFA target action date of December 12, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1347178/000162828026053308/vnda8-k852026exhibit991.htm)) |
| December 2026 | [BMS-986435 primary completion](https://sec-api.dev/pdufa/bms-986435) | BMY | Heart Failure | scheduled | "NCT06122779 (Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-14 (ESTIMATED); Lead Sponsor Bristol-Myers Squibb." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06122779)) |
| December 2026 | [Jemperli (dostarlimab) primary completion](https://sec-api.dev/pdufa/dostarlimab) | GSK | Carcinoma | scheduled | "NCT06317311 (A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-14 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06317311)) |
| December 2026 | [ABP-234 primary completion](https://sec-api.dev/pdufa/abp-234) | AMGN | Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC) | scheduled | "NCT06430866 (Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-14 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06430866)) |
| December 2026 | [PCV-20 primary completion](https://sec-api.dev/pdufa/pcv-20) | GSK | Chickenpox | scheduled | "NCT06806137 (A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12-14 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06806137)) |
| December 2026 | [NNC0662-0419 primary completion](https://sec-api.dev/pdufa/nnc0662-0419) | NVO | Overweight; Obesity | scheduled | "NCT07184632 (A Research Study on How Well Different Doses of the Medicine NNC0662-0419 Help People Living With Overweight or Obesity): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-12-14 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07184632)) |
| December 2026 | [IMAAVY (nipocalimab) primary completion](https://sec-api.dev/pdufa/nipocalimab) | JNJ | Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | scheduled | "NCT05327114 (Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2026-12-15 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05327114)) |
| December 2026 | [XL092 primary completion](https://sec-api.dev/pdufa/xl092) | EXEL | Non-Clear Cell Renal Cell Carcinoma | scheduled | "NCT05678673 (Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12-15 (ESTIMATED); Lead Sponsor Exelixis." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05678673)) |
| December 2026 | [Gefurulimab primary completion](https://sec-api.dev/pdufa/gefurulimab) | AZN | Generalized Myasthenia Gravis; gMG | scheduled | "NCT06607627 (PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12-15 (ESTIMATED); Lead Sponsor Alexion Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06607627)) |
| December 2026 | [CERUS CORP primary completion](https://sec-api.dev/companies/cers/catalysts) | CERS | Healthy Subjects | scheduled | "NCT07015437 (A Recovery and Lifespan Study Using INTERCEPT Red Blood Cells Prepared Using the INTERCEPT Blood System for RBCs With AS-1): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12-15 (ESTIMATED); Lead Sponsor Cerus Corporation." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07015437)) |

## By month

- [November 2026](https://sec-api.dev/fda-calendar/2026-11): 30 catalysts
- [December 2026](https://sec-api.dev/fda-calendar/2026-12): 74 catalysts
- [January 2027](https://sec-api.dev/fda-calendar/2027-01): 48 catalysts
- [February 2027](https://sec-api.dev/fda-calendar/2027-02): 50 catalysts
- [March 2027](https://sec-api.dev/fda-calendar/2027-03): 46 catalysts
- [April 2027](https://sec-api.dev/fda-calendar/2027-04): 44 catalysts
- [May 2027](https://sec-api.dev/fda-calendar/2027-05): 48 catalysts
- [June 2027](https://sec-api.dev/fda-calendar/2027-06): 43 catalysts
- [July 2027](https://sec-api.dev/fda-calendar/2027-07): 37 catalysts
- [August 2027](https://sec-api.dev/fda-calendar/2027-08): 32 catalysts
- [September 2027](https://sec-api.dev/fda-calendar/2027-09): 38 catalysts
- [October 2027](https://sec-api.dev/fda-calendar/2027-10): 35 catalysts
- [November 2027](https://sec-api.dev/fda-calendar/2027-11): 30 catalysts
- [December 2027](https://sec-api.dev/fda-calendar/2027-12): 43 catalysts
- [January 2028](https://sec-api.dev/fda-calendar/2028-01): 21 catalysts
- [February 2028](https://sec-api.dev/fda-calendar/2028-02): 33 catalysts
- [March 2028](https://sec-api.dev/fda-calendar/2028-03): 38 catalysts
- [April 2028](https://sec-api.dev/fda-calendar/2028-04): 20 catalysts
- [May 2028](https://sec-api.dev/fda-calendar/2028-05): 28 catalysts
- [June 2028](https://sec-api.dev/fda-calendar/2028-06): 48 catalysts
- [July 2028](https://sec-api.dev/fda-calendar/2028-07): 27 catalysts
- [August 2028](https://sec-api.dev/fda-calendar/2028-08): 29 catalysts
- [September 2028](https://sec-api.dev/fda-calendar/2028-09): 33 catalysts
- [October 2028](https://sec-api.dev/fda-calendar/2028-10): 20 catalysts
- [November 2028](https://sec-api.dev/fda-calendar/2028-11): 30 catalysts

## Feeds and downloads

- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "FDA calendar: upcoming PDUFA dates, advisory committees and readouts." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/fda-calendar

```bibtex
@misc{secapidev_fda_calendar_20261116,
  title        = {FDA calendar: upcoming PDUFA dates, advisory committees and readouts},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/fda-calendar}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_fda_calendar_20261116","title":"FDA calendar: upcoming PDUFA dates, advisory committees and readouts","publisher":"sec-api.dev","URL":"https://sec-api.dev/fda-calendar","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
